Cataplexy – Pipeline Insight, 2020
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “Cataplexy – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cataplexy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Cataplexy: Overview
Cataplexy is characterized by transient episodes of voluntary muscle weakness precipitated by intense emotion. The sudden onset of muscle weakness characterizes cataplexy. Such episodes are transient, lasting seconds to minutes, and get precipitated by intense emotions. Cataplectic attacks are more frequently incited by positive emotions (i.e., laughter, excitement, etc.) than negative emotions (i.e., anger, fear, frustration, etc.), with laughter being the most common precipitant. It is the complete or partial paralysis of voluntary muscles that is responsible for the weakness associated with cataplexy; however, it bears noting that the muscles of eye movement and respiration get spared during these attacks. The suppression of serotonergic and noradrenergic neuronal circuits permit the complete or partial paralysis of voluntary muscles.
Symptoms
The symptoms of Cataplexy include:
Diagnosis of cataplexy is carried out by studying sleep (polysomnogram), which records the muscles and brain involved in sleeping. Multiple sleep latency test examines short naps throughout the day to study how quicky the patient’s falls asleep during the spacing of naps.
Treatment
The following pharmacologic agents are considered first-line in the management of cataplexy: Selective serotonin reuptake inhibitors (fluoxetine 10 to 80 mg by mouth daily every morning), norepinephrine reuptake inhibitors (atomoxetine 40 to 80 mg by mouth daily every morning), serotonin/norepinephrine reuptake inhibitors (venlafaxine extended-release 37.5 to 150 mg by mouth once daily every morning), and tricyclic antidepressants (clomipramine 10 to 150 mg by mouth daily every morning). Tricyclic antidepressants (TCAs) have fallen out of favor for the treatment of cataplexy due to their anticholinergic side effects (i.e., delirium, dry mucous membranes, hyperthermia, ileus, mydriasis, tachycardia, and urinary retention). Sodium oxybate, the sodium salt of gamma-hydroxybutyrate has recently got approval from FDA for the treatment of Cataplexy.
Cataplexy Emerging Drugs Chapters
This segment of the Cataplexy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cataplexy Emerging Drugs
AXS12: Axome Therapeutics
AXS12 (Reboxetine) is a Phase 2 drug in development for the treatment of cataplexy. It acts as adrenergic uptake inhibitor and is currently being developed by Axome Therapeutics.
Further product details are provided in the report
Cataplexy: Therapeutic Assessment
This segment of the report provides insights about the different Cataplexy drugs segregated based on following parameters that define the scope of the report, such as:
Cataplexy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cataplexy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cataplexy drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Cataplexy – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cataplexy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Cataplexy: Overview
Cataplexy is characterized by transient episodes of voluntary muscle weakness precipitated by intense emotion. The sudden onset of muscle weakness characterizes cataplexy. Such episodes are transient, lasting seconds to minutes, and get precipitated by intense emotions. Cataplectic attacks are more frequently incited by positive emotions (i.e., laughter, excitement, etc.) than negative emotions (i.e., anger, fear, frustration, etc.), with laughter being the most common precipitant. It is the complete or partial paralysis of voluntary muscles that is responsible for the weakness associated with cataplexy; however, it bears noting that the muscles of eye movement and respiration get spared during these attacks. The suppression of serotonergic and noradrenergic neuronal circuits permit the complete or partial paralysis of voluntary muscles.
Symptoms
The symptoms of Cataplexy include:
- Dropping eyelids
- Jaw dropping
- Head falling to the side due to neck muscle weakness
- Whole body falling to the ground
- Various muscles around your body twitching without an obvious cause
Diagnosis of cataplexy is carried out by studying sleep (polysomnogram), which records the muscles and brain involved in sleeping. Multiple sleep latency test examines short naps throughout the day to study how quicky the patient’s falls asleep during the spacing of naps.
Treatment
The following pharmacologic agents are considered first-line in the management of cataplexy: Selective serotonin reuptake inhibitors (fluoxetine 10 to 80 mg by mouth daily every morning), norepinephrine reuptake inhibitors (atomoxetine 40 to 80 mg by mouth daily every morning), serotonin/norepinephrine reuptake inhibitors (venlafaxine extended-release 37.5 to 150 mg by mouth once daily every morning), and tricyclic antidepressants (clomipramine 10 to 150 mg by mouth daily every morning). Tricyclic antidepressants (TCAs) have fallen out of favor for the treatment of cataplexy due to their anticholinergic side effects (i.e., delirium, dry mucous membranes, hyperthermia, ileus, mydriasis, tachycardia, and urinary retention). Sodium oxybate, the sodium salt of gamma-hydroxybutyrate has recently got approval from FDA for the treatment of Cataplexy.
Cataplexy Emerging Drugs Chapters
This segment of the Cataplexy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cataplexy Emerging Drugs
- FT218: Avadel
AXS12: Axome Therapeutics
AXS12 (Reboxetine) is a Phase 2 drug in development for the treatment of cataplexy. It acts as adrenergic uptake inhibitor and is currently being developed by Axome Therapeutics.
Further product details are provided in the report
Cataplexy: Therapeutic Assessment
This segment of the report provides insights about the different Cataplexy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Cataplexy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Cataplexy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cataplexy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cataplexy drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Cataplexy R&D. The therapies under development are focused on novel approaches to treat/improve Cataplexy.
- Cataplexy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Cataplexy drugs?
- How many Cataplexy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cataplexy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cataplexy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Cataplexy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Avadel
- Axome Therapeutics
- FT218
- AXS12
Introduction
Executive Summary
Cataplexy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cataplexy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cataplexy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cataplexy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
FT218: Avadel
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
AXS12: Axome Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Cataplexy Key Companies
Cataplexy Key Products
Cataplexy- Unmet Needs
Cataplexy- Market Drivers and Barriers
Cataplexy- Future Perspectives and Conclusion
Cataplexy Analyst Views
Cataplexy Key Companies
Appendix
Executive Summary
Cataplexy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Cataplexy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Cataplexy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Cataplexy Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
FT218: Avadel
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
AXS12: Axome Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Cataplexy Key Companies
Cataplexy Key Products
Cataplexy- Unmet Needs
Cataplexy- Market Drivers and Barriers
Cataplexy- Future Perspectives and Conclusion
Cataplexy Analyst Views
Cataplexy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Cataplexy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Cataplexy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Cataplexy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Cataplexy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
